Literature DB >> 23758978

Tailored rectal cancer treatment--a time for implementing contemporary prognostic factors?

A Wibe1, W L Law, V Fazio, C P Delaney.   

Abstract

AIM: To report data supporting the development of tailored treatment strategies for rectal cancer.
METHOD: A comprehensive review of the literature on the impact of prognostic factors cur-rently not included in international guidelines in rectal cancer management.
RESULTS: There is considerable variation in treatment guidelines for rectal cancer worldwide, especially for Stage II and Stage III disease. Long-term side effects of chemoradiotherapy are not considered in any guideline. Detailed knowledge, and the prognostic impact, of the circumferential resection margin, tumour grade and venous invasion should be factored into the development of a treatment strategy.
CONCLUSION: Factors additional to the TNM system should improve decision making for contemporary rectal cancer treatment. Optimized radiological and pathological evaluations, and a focus on detailed clinical factors, should be the basis for treatment decisions. International guidelines should consider all known prognostic factors for long-term oncological and functional outcomes. Colorectal Disease
© 2013 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  MRI; Rectal cancer; prognostic factors; tailored treatment

Mesh:

Year:  2013        PMID: 23758978     DOI: 10.1111/codi.12317

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  6 in total

1.  Complications and risk prediction in treatment of elderly patients with rectal cancer.

Authors:  T Stornes; A Wibe; B H Endreseth
Journal:  Int J Colorectal Dis       Date:  2015-08-23       Impact factor: 2.571

Review 2.  State of the Art - Rectal Cancer Surgery.

Authors:  Andreas Bogner; Johanna Kirchberg; Jürgen Weitz; Johannes Fritzmann
Journal:  Visc Med       Date:  2019-06-27

3.  Protocol for a multicentre randomised feasibility trial evaluating early Surgery Alone In LOw Rectal cancer (SAILOR).

Authors:  Dean A Harris; Kymberley Thorne; Hayley Hutchings; Saiful Islam; Gail Holland; Olivia Hatcher; Sarah Gwynne; Ian Jenkins; Peter Coyne; Michael Duff; Melanie Feldman; Des C Winter; Simon Gollins; Phil Quirke; Nick West; Gina Brown; Deborah Fitzsimmons; Alan Brown; John Beynon
Journal:  BMJ Open       Date:  2016-11-21       Impact factor: 2.692

4.  Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma.

Authors:  Lorenzo Ferrando; Gabriella Cirmena; Anna Garuti; Stefano Scabini; Federica Grillo; Luca Mastracci; Edoardo Isnaldi; Ciro Marrone; Roberta Gonella; Roberto Murialdo; Roberto Fiocca; Emanuele Romairone; Alberto Ballestrero; Gabriele Zoppoli
Journal:  PLoS One       Date:  2020-02-05       Impact factor: 3.240

5.  Preoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212).

Authors:  Masayuki Ohue; Shin Fujita; Junki Mizusawa; Yukihide Kanemitsu; Tetsuya Hamaguchi; Shunsuke Tsukamoto; Shingo Noura; Masayoshi Yasui; Masaaki Itoh; Akio Shiomi; Koji Komori; Jun Watanabe; Yoshihiro Akazai; Manabu Shiozawa; Takashi Yamaguchi; Hiroyuki Bandou; Kenji Katsumata; Yoshihiro Moriya
Journal:  Jpn J Clin Oncol       Date:  2022-02-05       Impact factor: 3.019

6.  Pretreatment magnetic resonance imaging of regional lymph nodes with carcinoembryonic antigen in prediction of synchronous distant metastasis in patients with rectal cancer.

Authors:  Huanhuan Liu; Yanfen Cui; Wei Shen; Xingwen Fan; Long Cui; Caiyuan Zhang; Gang Ren; Jihong Fu; Dengbin Wang
Journal:  Oncotarget       Date:  2016-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.